Boiron SA (0DTF.L)
EUR 27.0
(-0.37%)
EUR 27.0
(-0.37%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -60.34 Million EUR | 73.62% |
| 2022 | -228.77 Million EUR | -3.1% |
| 2021 | -221.89 Million EUR | 0.16% |
| 2020 | -222.25 Million EUR | -13.73% |
| 2019 | -195.42 Million EUR | 7.49% |
| 2018 | -211.25 Million EUR | 18.44% |
| 2017 | -259.03 Million EUR | -10.2% |
| 2016 | -235.05 Million EUR | -25.95% |
| 2015 | -186.62 Million EUR | -23.45% |
| 2014 | -151.17 Million EUR | 2.87% |
| 2013 | -155.64 Million EUR | -71.47% |
| 2012 | -90.77 Million EUR | -4.96% |
| 2011 | -86.48 Million EUR | 9.03% |
| 2010 | -95.06 Million EUR | -1.02% |
| 2009 | -94.1 Million EUR | -30.59% |
| 2008 | -72.05 Million EUR | -56.94% |
| 2007 | -45.91 Million EUR | -245.0% |
| 2006 | -13.3 Million EUR | -2296.2% |
| 2005 | 606 Thousand EUR | 101.67% |
| 2004 | -36.18 Million EUR | -794.0% |
| 2003 | -4.04 Million EUR | -879.9% |
| 2002 | -413 Thousand EUR | 97.24% |
| 2001 | -14.94 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -49.29 Million EUR | 0.0% |
| 2023 Q2 | -219.57 Million EUR | 0.0% |
| 2023 Q4 | -60.34 Million EUR | 0.0% |
| 2023 FY | -60.34 Million EUR | 73.62% |
| 2022 FY | -228.77 Million EUR | -3.1% |
| 2022 Q4 | -228.77 Million EUR | 0.0% |
| 2022 Q2 | -218.81 Million EUR | 0.0% |
| 2021 Q4 | -221.89 Million EUR | 0.0% |
| 2021 Q2 | -202.45 Million EUR | 0.0% |
| 2021 FY | -221.89 Million EUR | 0.16% |
| 2020 FY | -222.25 Million EUR | -13.73% |
| 2020 Q2 | -205.47 Million EUR | 0.0% |
| 2020 Q4 | -222.25 Million EUR | 0.0% |
| 2019 Q2 | -165.29 Million EUR | 0.0% |
| 2019 Q4 | -195.42 Million EUR | 0.0% |
| 2019 FY | -195.42 Million EUR | 7.49% |
| 2018 Q2 | -175.51 Million EUR | 0.0% |
| 2018 Q4 | -211.25 Million EUR | 0.0% |
| 2018 FY | -211.25 Million EUR | 18.44% |
| 2017 Q4 | -259.03 Million EUR | 0.0% |
| 2017 FY | -259.03 Million EUR | -10.2% |
| 2017 Q2 | -205.94 Million EUR | 0.0% |
| 2016 FY | -235.05 Million EUR | -25.95% |
| 2016 Q4 | -235.05 Million EUR | 0.0% |
| 2016 Q2 | -182.51 Million EUR | 0.0% |
| 2015 Q4 | -186.62 Million EUR | 0.0% |
| 2015 Q2 | -140.08 Million EUR | 0.0% |
| 2015 FY | -186.62 Million EUR | -23.45% |
| 2014 Q4 | -151.17 Million EUR | 0.0% |
| 2014 FY | -151.17 Million EUR | 2.87% |
| 2014 Q2 | -134.88 Million EUR | 0.0% |
| 2013 Q2 | -100.71 Million EUR | 0.0% |
| 2013 Q4 | -155.64 Million EUR | 0.0% |
| 2013 FY | -155.64 Million EUR | -71.47% |
| 2012 Q2 | -72.1 Million EUR | 6.66% |
| 2012 Q1 | -77.25 Million EUR | 10.68% |
| 2012 Q4 | -90.77 Million EUR | 5.96% |
| 2012 FY | -90.77 Million EUR | -4.96% |
| 2012 Q3 | -96.52 Million EUR | -33.86% |
| 2011 Q2 | -60.08 Million EUR | 0.0% |
| 2011 FY | -86.48 Million EUR | 9.03% |
| 2011 Q4 | -86.48 Million EUR | 0.0% |
| 2010 Q4 | -95.06 Million EUR | 0.0% |
| 2010 FY | -95.06 Million EUR | -1.02% |
| 2010 Q2 | -45.38 Million EUR | 0.0% |
| 2009 Q4 | -94.1 Million EUR | 0.0% |
| 2009 FY | -94.1 Million EUR | -30.59% |
| 2008 FY | -72.05 Million EUR | -56.94% |
| 2007 FY | -45.91 Million EUR | -245.0% |
| 2006 FY | -13.3 Million EUR | -2296.2% |
| 2005 FY | 606 Thousand EUR | 101.67% |
| 2004 FY | -36.18 Million EUR | -794.0% |
| 2003 FY | -4.04 Million EUR | -879.9% |
| 2002 FY | -413 Thousand EUR | 97.24% |
| 2001 FY | -14.94 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Laboratorios Farmaceuticos Rovi, S.A. | 21.31 Million EUR | 383.123% |
| Vetoquinol SA | -129.83 Million EUR | 53.524% |
| Valneva SE | 82.73 Million EUR | 172.933% |
| AB Science S.A. | 13.03 Million EUR | 562.923% |
| Nanobiotix S.A. | -29.8 Million EUR | -102.49% |
| PHAXIAM Therapeutics S.A. | -275 Thousand EUR | -21842.545% |
| Vivoryon Therapeutics N.V. | -18.52 Million EUR | -225.75% |
| BioSenic S.A. | 28.04 Million EUR | 315.169% |
| ABIVAX Société Anonyme | -196.47 Million EUR | 69.288% |
| Formycon AG | 2.45 Million EUR | 2561.934% |